Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

References

• Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19(14):3977–12. doi:10.1158/1078-0432.CCR-12-3243.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312–318. doi:10.1158/2326-6066.CIR-16-0237.
   PubMed Web of Science ®Google Scholar
• Shulgin B, Kosinsky Y, Omelchenko A, Chu L, Mugundu G, Aksenov S, Pimentel R, DeYulia G, Kim G, Peskov K, et al. Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. OncoImmunology. 2020;9(1):1748982. doi:10.1080/2162402X.2020.1748982.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017;86:358–363. doi:10.1016/j.ejca.2017.09.032.
   PubMed Web of Science ®Google Scholar
• Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22(6):1364–1370. doi:10.1158/1078-0432.CCR-15-0491.
   PubMed Web of Science ®Google Scholar
• Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol. 2004;4(7):553–564. doi:10.1038/nri1394.
   PubMed Web of Science ®Google Scholar
• Marchant A, Goldman M. T cell-mediated immune responses in human newborns: ready to learn? Clin Exp Immunol. 2005;141(1):10–18. doi:10.1111/j.1365-2249.2005.02799.x.
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405–413. doi:10.1016/1074-7613(94)90071-X.
   PubMed Web of Science ®Google Scholar
• Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 1950;1999:5813–5820.
   Google Scholar
• Pandiyan P, Hegel JKE, Krueger M, Quandt D, Brunner-Weinzierl MC. High IFN-gamma production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4). J Immunol 2007;178(4):2132–2140. doi:10.4049/jimmunol.178.4.2132.
   PubMed Web of Science ®Google Scholar
• Pierau M, Lingel H, Vogel K, Arra A, Brunner-Weinzierl MC. CTLA-4-competent conventional T cells back up regulatory T cells to restrain memory T-helper type 2 cell responses. Allergy. 2020;75(3):684–687. doi:10.1111/all.14042.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12:116.
   Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–164. doi:10.1016/S1470-2045(09)70334-1.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen -T-T, Berman DM, Wolchok JD, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894. doi:10.1200/JCO.2014.56.2736.
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–1028. doi:10.1056/NEJMoa063842.
   PubMed Web of Science ®Google Scholar
• Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010;161(3):512–526. doi:10.1111/j.1476-5381.2010.00922.x.
   PubMed Web of Science ®Google Scholar
• Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med. 2009;206(7):1525–1534. doi:10.1084/jem.20090504.
   PubMed Web of Science ®Google Scholar
• Darrah PA, Patel DT, De Luca PM, Lindsay RWB, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007;13(7):843–850. doi:10.1038/nm1592.
   PubMed Web of Science ®Google Scholar
• Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, et al. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013;3(4):418–429. doi:10.1158/2159-8290.CD-12-0383.
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design (nature reviews immunology (2008) 8, (247-258)). Nat Rev Immunol. 2008;8(6):486. doi:10.1038/nri2355.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-10 production by effector T cells: th1 cells show self control. J Exp Med. 2007;204(2):239–243. https://pubmed.ncbi.nlm.nih.gov/17296790.
   PubMed Web of Science ®Google Scholar
• Adkins B, Williamson T, Guevara P, Bu Y. Murine neonatal lymphocytes show rapid early cell cycle entry and cell division. J Immunol 1950;2003:4548–4556.
   Google Scholar
• Smith NL, Wissink E, Wang J, Pinello JF, Davenport MP, Grimson A, Rudd BD. Rapid proliferation and differentiation impairs the development of memory CD8+ T cells in early life. J Immunol. 2014;193(1):177–184. doi:10.4049/jimmunol.1400553.
   PubMed Web of Science ®Google Scholar
• Krummey SM, Cheeseman JA, Conger JA, Jang PS, Mehta AK, Kirk AD, Larsen CP, Ford ML. High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. Am J Transplant. 2014;14(3):607–614. doi:10.1111/ajt.12600.
   PubMed Web of Science ®Google Scholar
• Lingel H, Wissing J, Arra A, Schanze D, Lienenklaus S, Klawonn F, Pierau M, Zenker M, Jänsch L, Brunner-Weinzierl MC, et al. CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation. Cell Death Differ. 2017;24(10):1739–1749. doi:10.1038/cdd.2017.102.
   PubMed Web of Science ®Google Scholar
• Hebel K, Rudolph M, Kosak B, Chang H-D, Butzmann J, Brunner-Weinzierl MC. IL-1β and TGF-β act antagonistically in induction and differentially in propagation of human proinflammatory precursor CD4+ T cells. J Immunol 1950;2011:5627–5635.
   Google Scholar
• Kugelberg E. Babies‘ T cells can fight. Nat Rev Immunol. 2014;14(11):714–715. doi:10.1038/nri3758.
   PubMed Web of Science ®Google Scholar
• Gibbons D, Fleming P, Virasami A, Michel M-L, Sebire NJ, Costeloe K, Carr R, Klein N, Hayday A. Interleukin-8 (CXCL8) production is a signatory T cell effector function of human newborn infants. Nat Med. 2014;20(10):1206–1210. doi:10.1038/nm.3670.
   PubMed Web of Science ®Google Scholar
• Oosterwegel MA, Mandelbrot DA, Boyd SD, Lorsbach RB, Jarrett DY, Abbas AK, Sharpe AH. The role of CTLA-4 in regulating Th2 differentiation. J Immunol. 1999;163:2634–2639.
   PubMed Web of Science ®Google Scholar
• Orbach D, Sarnacki S, Brisse HJ, Gauthier-Villars M, Jarreau P-H, Tsatsaris V, Baruchel A, Zerah M, Seigneur E, Peuchmaur M, et al. Neonatal cancer. Lancet Oncol. 2013;14(13):e609–20. doi:10.1016/S1470-2045(13)70236-5.
   PubMed Web of Science ®Google Scholar
• Moore SW, Satgé D, Sasco AJ, Zimmermann A, Plaschkes J. The epidemiology of neonatal tumours. Report of an international working group. Pediatr Surg Int. 2003;19(7):509–519. doi:10.1007/s00383-003-1048-8.
   PubMed Web of Science ®Google Scholar
• Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. Cancer J Clin. 2014;64(2):83–103. doi:10.3322/caac.21219.
   PubMed Web of Science ®Google Scholar
• Curtin SC, Minino AM, Anderson RN. Declines in cancer death rates among children and adolescents in the United States, 1999–2014. NCHS Data Brief. 2016;257:1–8.
   Google Scholar
• Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019;38(4):573–594. doi:10.1007/s10555-019-09819-z.
   PubMed Web of Science ®Google Scholar
• Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA, et al. Immunotherapeutic challenges for pediatric cancers. Mol Ther Oncolytics. 2019;15:38–48. doi:10.1016/j.omto.2019.08.005.
   PubMed Web of Science ®Google Scholar
• Park JA, Cheung N-KV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treat Rev. 2017;58:22–33. doi:10.1016/j.ctrv.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Marshall GM, Carter DR, Cheung BB, Liu T, Mateos MK, Meyerowitz JG, Weiss WA. The prenatal origins of cancer. Nat Rev Cancer. 2014;14(4):277–289. doi:10.1038/nrc3679.
   PubMed Web of Science ®Google Scholar
• Rudolph M, Hebel K, Miyamura Y, Maverakis E, Brunner-Weinzierl MC. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo. J Immunol. 2011;186(10):5580–5589. doi:10.4049/jimmunol.1003381.
   PubMed Web of Science ®Google Scholar
• Hoff H, Knieke K, Cabail Z, Hirseland H, Vratsanos G, Burmester G-R. Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28 null T cells. J Immunol. 2009;182:5342–5351. doi:10.4049/jimmunol.0801624.
   PubMed Web of Science ®Google Scholar
• Pandiyan P, Gärtner D, Soezeri O, Radbruch A, Schulze-Osthoff K, Brunner-Weinzierl MC. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med. 2004;199:831–842.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–iv142. doi:10.1093/annonc/mdx225.
   PubMed Web of Science ®Google Scholar
• Morgado M, Plácido A, Morgado S, Roque F. Management of the adverse effects of immune checkpoint inhibitors. Vaccines. 2020;8(4):8. doi:10.3390/vaccines8040575.
   Web of Science ®Google Scholar
• Arra A, Lingel H, Kuropka B, Pick J, Schnoeder T, Fischer T, Freund C, Pierau M, Brunner-Weinzierl MC. The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs. OncoImmunology. 2017;6(2):e1273300. doi:10.1080/2162402X.2016.1273300.
   PubMed Web of Science ®Google Scholar
• Brunner-Weinzierl MC, Rudd CE. CTLA-4 and PD-1 control of T-cell motility and migration: implications for tumor immunotherapy. Front Immunol. 2018;9:2737. doi:10.3389/fimmu.2018.02737.
   PubMed Web of Science ®Google Scholar
• Loevenich K, Ueffing K, Abel S, Hose M, Matuschewski K, Westendorf AM. DC-derived IL-10 modulates pro-inflammatory cytokine production and promotes induction of CD4+IL-10+ regulatory T cells during plasmodium yoelii infection. Front Immunol. 2017;8:152. doi:10.3389/fimmu.2017.00152.
   PubMed Web of Science ®Google Scholar
• Smith LK, Boukhaled GM, Condotta SA, Mazouz S, Guthmiller JJ, Vijay R, Butler NS, Bruneau J, Shoukry NH, Krawczyk CM, et al. Interleukin-10 directly inhibits CD8+ T cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity. 2018;48(299–312.e5):299–312.e5. doi:10.1016/j.immuni.2018.01.006.
   PubMed Web of Science ®Google Scholar
• Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med. 2006;203:2461–2472. doi:10.1084/jem.20061462.
   PubMed Web of Science ®Google Scholar
• Busse D, La Rosa De M, Hobiger K, Thurley K, Flossdorf M, Scheffold A, Hofer T. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Natl Acad Sci U S A. 2010;107:3058–3063. doi:10.1073/pnas.0812851107.
   PubMed Web of Science ®Google Scholar
• Häringer B, Lozza L, Steckel B, Geginat J. Identification and characterization of IL-10/IFN-γ–producing effector-like T cells with regulatory function in human blood. J Exp Med. 2009;206(5):1009–1017. doi:10.1084/jem.20082238.
   PubMed Web of Science ®Google Scholar
• Vogel K, Pierau M, Arra A, Lampe K, Schlueter D, Arens C, Brunner-Weinzierl MC. Developmental induction of human T-cell responses against Candida albicans and Aspergillus fumigatus. Sci Rep. 2018;8(1):16904. doi:10.1038/s41598-018-35161-5.
   PubMed Web of Science ®Google Scholar
• Breiman L. Random Forests. Mach Learn. 2001;45(1):5–32. doi:10.1023/A:1010933404324.
   Web of Science ®Google Scholar
• Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O. Scikit-learn: machine Learning in Python; 2011. https://arxiv.org/abs/1201.0490 .
   Google Scholar
• Chinchor N. MUC-4 evaluation metrics. Proceedings of the 4th Conference on Message Understanding. MUC4 ’92; 1992. USA: Association for Computational Linguistics. 22–29.
   Google Scholar